Valentina Sarao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Valentina Sarao has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Daniele Veritti
Department of Medicine-Ophthalmology, University of Udine, Udine, Italy
17 shared publications - Paolo Lanzetta
Department of Medicine-Ophthalmology, University of Udine, Udine, Italy
17 shared publications Asia Amelia Martin
Department of Medicine-Ophthalmology, University of Udine, Udine, Italy
2 shared publications- Enrico Borrelli
Department of Surgical Sciences, University of Turin, Turin, Italy
2 shared publications - Federico Ricci
Department of Experimental Medicine and Surgery, Retina Unit, University of Rome Tor Vergata, Rome, Italy
2 shared publications Francesco Bonini
Department of Medicine-Ophthalmology, University of Udine, Udine, Italy
2 shared publications
Latest Publications
- Open Access
- 6 July 2026
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
Switching to aflibercept 8 mg in neovascular age-related macular degeneration: real-world outcomes according to switch indication
Purpose: To evaluate visual and anatomical outcomes after switching to aflibercept 8 mg in eyes with neovascular age-related macular degeneration (nAMD), and to assess outcomes according to the clinical indication for switching. Methods: Multicentre retrospective observational study including 300 eyes with nAMD previously treated with anti-vascular endothelial growth factor therapy and switched to aflibercept 8 mg for non-response (n:74, 24.7%), suboptimal response (n:159, 53.0%), or durability-driven reasons (n:67, 22.3%). Longitudinal data from the 6 months preceding the switch and post-switch visits at 3 and 6 months were analyzed. The primary outcome was change in best-corrected visual acuity (BCVA, ETDRS letters) from the switch visit to the 3-month post-switch visit. Secondary outcomes included changes in central subfield thickness (CST) and retinal fluid status. Results: During the pre-switch period, mean BCVA declined by − 1.9 ± 8.2 letters and CST increased. At 3 months after switching, BCVA improved by + 2.0 ± 9.2 letters (95% CI, + 0.8 to + 3.2; p < 0.01), with greater gains in eyes switched for non-response (+ 2.8 ± 12.6 letters). Mean CST decreased by − 45.3 ± 79.8 µm (95% CI, − 55.4 to − 35.2; p < 0.001), with corresponding reductions in retinal fluid. Anatomical improvements were more pronounced in eyes switched for non-response, whereas more modest but consistent changes were observed in suboptimal and durability-driven groups. Visual and anatomical outcomes were maintained at 6 months. Conclusions: In previously treated nAMD eyes, switching to aflibercept 8 mg was associated with reversal of pre-switch anatomical worsening, reduction in retinal fluid, and modest visual gains. Greater responses were observed in eyes with inadequate pre-switch disease control, supporting its role as a treatment escalation strategy in clinical practice.
- 6 July 2026
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
Open AccessSwitching to aflibercept 8 mg in neovascular age-related macular degeneration: real-world outcomes according to switch indication
Purpose: To evaluate visual and anatomical outcomes after switching to aflibercept 8 mg in eyes with neovascular age-related macular degeneration (nAMD), and to assess outcomes according to the clinical indication for switching. Methods: Multicentre retrospective observational study including 300 eyes with nAMD previously treated with anti-vascular endothelial growth factor therapy and switched to aflibercept 8 mg for non-response (n:74, 24.7%), suboptimal response (n:159, 53.0%), or durability-driven reasons (n:67, 22.3%). Longitudinal data from the 6 months preceding the switch and post-switch visits at 3 and 6 months were analyzed. The primary outcome was change in best-corrected visual acuity (BCVA, ETDRS letters) from the switch visit to the 3-month post-switch visit. Secondary outcomes included changes in central subfield thickness (CST) and retinal fluid status. Results: During the pre-switch period, mean BCVA declined by − 1.9 ± 8.2 letters and CST increased. At 3 months after switching, BCVA improved by + 2.0 ± 9.2 letters (95% CI, + 0.8 to + 3.2; p < 0.01), with greater gains in eyes switched for non-response (+ 2.8 ± 12.6 letters). Mean CST decreased by − 45.3 ± 79.8 µm (95% CI, − 55.4 to − 35.2; p < 0.001), with corresponding reductions in retinal fluid. Anatomical improvements were more pronounced in eyes switched for non-response, whereas more modest but consistent changes were observed in suboptimal and durability-driven groups. Visual and anatomical outcomes were maintained at 6 months. Conclusions: In previously treated nAMD eyes, switching to aflibercept 8 mg was associated with reversal of pre-switch anatomical worsening, reduction in retinal fluid, and modest visual gains. Greater responses were observed in eyes with inadequate pre-switch disease control, supporting its role as a treatment escalation strategy in clinical practice.
- 22 June 2026
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- p. 1-2
Comment to: Hashiya N, Maruko I, Maruko R et al. Increased intraocular pressure immediately after aflibercept 8 mg intravitreal injection for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol (2026) 264:1611–1617. doi:10.1007/s00417-026-07117-3
- 22 June 2026
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- p. 1-2
Comment to: Hashiya N, Maruko I, Maruko R et al. Increased intraocular pressure immediately after aflibercept 8 mg intravitreal injection for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol (2026) 264:1611–1617. doi:10.1007/s00417-026-07117-3
- Open Access
- 25 February 2026
- Published by Springer Nature in Eye
- Vol. 40 (7) , 979-985
AI-assisted analysis of early fluid dynamics following aflibercept 8 mg in treatment-naïve neovascular AMD
Purpose: To evaluate early morphological changes following intravitreal aflibercept 8 mg in treatment-naïve neovascular age-related macular degeneration (nAMD) using artificial intelligence (AI)-assisted optical coherence tomography (OCT) segmentation. Methods: Thirty eyes with treatment-naïve subfoveal nAMD received three monthly aflibercept 8 mg injections. OCT scans were obtained at baseline and days 1, 7, 14, 30, 60, and 90. AI-based segmentation software (Fluid Monitor, RetInSight GmbH) quantified intraretinal fluid (IRF), subretinal fluid (SRF), and pigment epithelial detachment (PED) volumes in the central 6-mm area. Morphologic changes were correlated with best-corrected visual acuity (BCVA). Results: IRF, SRF, and PED showed distinct reduction patterns. In eyes with IRF ( n = 22), mean volume decreased by 65% at day 1, 94% at day 14, and 96% at day 90 ( p < 0.05). Among eyes with SRF ( n = 28), SRF volume decreased by 18%, 84%, and 99% at days 1, 14, and 90, respectively ( p ≤ 0.002). PED volume declined more gradually among affected eyes ( n = 23), with mean reductions of 7% at day 1, 34% by day 14, and 53% by day 90 ( p ≤ 0.023). BCVA improved from 51.8 ± 14.4 to 62.6 ± 14.4 ETDRS letters by day 90 (mean gain + 10.8; p < 0.001). Multivariate regression identified a significant association between IRF reduction at day 14 and BCVA gain at day 90 ( β = −0.018, p = 0.036). Conclusions: Aflibercept 8 mg induced rapid, compartment-specific morphologic responses in treatment-naïve nAMD, with early IRF resolution and significant BCVA improvement. AI-assisted analysis provided detailed pharmacodynamic insights and may support individualised treatment strategies during the loading phase.
- 25 February 2026
- Published by Springer Nature in Eye
- Vol. 40 (7) , 979-985
Open AccessAI-assisted analysis of early fluid dynamics following aflibercept 8 mg in treatment-naïve neovascular AMD
Purpose: To evaluate early morphological changes following intravitreal aflibercept 8 mg in treatment-naïve neovascular age-related macular degeneration (nAMD) using artificial intelligence (AI)-assisted optical coherence tomography (OCT) segmentation. Methods: Thirty eyes with treatment-naïve subfoveal nAMD received three monthly aflibercept 8 mg injections. OCT scans were obtained at baseline and days 1, 7, 14, 30, 60, and 90. AI-based segmentation software (Fluid Monitor, RetInSight GmbH) quantified intraretinal fluid (IRF), subretinal fluid (SRF), and pigment epithelial detachment (PED) volumes in the central 6-mm area. Morphologic changes were correlated with best-corrected visual acuity (BCVA). Results: IRF, SRF, and PED showed distinct reduction patterns. In eyes with IRF ( n = 22), mean volume decreased by 65% at day 1, 94% at day 14, and 96% at day 90 ( p < 0.05). Among eyes with SRF ( n = 28), SRF volume decreased by 18%, 84%, and 99% at days 1, 14, and 90, respectively ( p ≤ 0.002). PED volume declined more gradually among affected eyes ( n = 23), with mean reductions of 7% at day 1, 34% by day 14, and 53% by day 90 ( p ≤ 0.023). BCVA improved from 51.8 ± 14.4 to 62.6 ± 14.4 ETDRS letters by day 90 (mean gain + 10.8; p < 0.001). Multivariate regression identified a significant association between IRF reduction at day 14 and BCVA gain at day 90 ( β = −0.018, p = 0.036). Conclusions: Aflibercept 8 mg induced rapid, compartment-specific morphologic responses in treatment-naïve nAMD, with early IRF resolution and significant BCVA improvement. AI-assisted analysis provided detailed pharmacodynamic insights and may support individualised treatment strategies during the loading phase.
- Open Access
- 7 November 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (22) , 7893
AI-Assisted OCT Clinical Phenotypes of Diabetic Macular Edema: A Large Cohort Clustering Study
Purpose: To characterize, using clustering analysis, the OCT morphological and clinical phenotypes of diabetic macular edema (DME) in a very large population (>2000 DME eyes) using standardized and validated OCT-based biomarkers. Methods: A cross-sectional study was conducted on OCT scans collected from 2355 eyes of 1688 patients with DME and performed during real-world clinical practice. OCT scans were automatically analyzed by a software able to automatically quantify OCT key biomarkers: intraretinal fluid (IRF), subretinal fluid (SRF), hyperreflective retinal foci (I-HRF), and external limiting membrane (ELM) and ellipsoid zone (EZ) interruption. Clustering analysis was performed using the above-mentioned biomarkers, including the distribution of IRF across the three ETDRS rings. Results: The overall population was predominantly composed of type 2 diabetes patients (89%), with a mean diabetes duration of 15.6 ± 10.7 years and mean best corrected visual acuity (BCVA) of 63 ± 18 ETDRS letters. Multivariate clustering identified four morphological phenotypes with distinct patterns of fluid distribution associated with different I-HRF counts, SRF volume, and percentages of ELM/EZ integrity (p < 0.0001). Conclusions: This large OCT analysis identified distinct morphological subtypes of DME, confirming the clinical relevance of key imaging biomarkers. The distribution and severity of DME features differ among clusters, supporting the importance of OCT-based phenotyping in tailoring treatment strategies and understanding disease evolution.
- 7 November 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (22) , 7893
Open AccessAI-Assisted OCT Clinical Phenotypes of Diabetic Macular Edema: A Large Cohort Clustering Study
Purpose: To characterize, using clustering analysis, the OCT morphological and clinical phenotypes of diabetic macular edema (DME) in a very large population (>2000 DME eyes) using standardized and validated OCT-based biomarkers. Methods: A cross-sectional study was conducted on OCT scans collected from 2355 eyes of 1688 patients with DME and performed during real-world clinical practice. OCT scans were automatically analyzed by a software able to automatically quantify OCT key biomarkers: intraretinal fluid (IRF), subretinal fluid (SRF), hyperreflective retinal foci (I-HRF), and external limiting membrane (ELM) and ellipsoid zone (EZ) interruption. Clustering analysis was performed using the above-mentioned biomarkers, including the distribution of IRF across the three ETDRS rings. Results: The overall population was predominantly composed of type 2 diabetes patients (89%), with a mean diabetes duration of 15.6 ± 10.7 years and mean best corrected visual acuity (BCVA) of 63 ± 18 ETDRS letters. Multivariate clustering identified four morphological phenotypes with distinct patterns of fluid distribution associated with different I-HRF counts, SRF volume, and percentages of ELM/EZ integrity (p < 0.0001). Conclusions: This large OCT analysis identified distinct morphological subtypes of DME, confirming the clinical relevance of key imaging biomarkers. The distribution and severity of DME features differ among clusters, supporting the importance of OCT-based phenotyping in tailoring treatment strategies and understanding disease evolution.
- 2 June 2025
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 263 (10) , 2985-2987
Extended duration of VEGF inhibition with aflibercept 8 mg: the role of reduced ocular clearance
- 2 June 2025
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 263 (10) , 2985-2987
Extended duration of VEGF inhibition with aflibercept 8 mg: the role of reduced ocular clearance
- 1 April 2025
- Published by Springer Nature in Eye
- Vol. 39 (10) , 1933-1939
Early intraocular pressure dynamics following aflibercept 8 mg versus aflibercept 2 mg: a propensity score-matched analysis
Purpose To compare early intraocular pressure (IOP) dynamics following intravitreal injections of aflibercept 8 mg versus aflibercept 2 mg using propensity score-matched analysis with fellow eye controls. Methods This prospective observational study included treatment-naïve patients with neovascular age-related macular degeneration (AMD) or diabetic macular oedema (DMO). Patients received aflibercept 8 mg or 2 mg based on investigator discretion. IOP was measured using iCare rebound tonometry at baseline (T0), 1 min (T1), 10 min (T2), 30 min (T3), and 3 months (T4) after the initial treatment. Untreated fellow eyes served as controls. Secondary analyses evaluated predictors of significant IOP elevation. Results A total of 1820 IOP measurements from 140 eyes (35 treated with aflibercept 8 mg and 35 with aflibercept 2 mg and their respective untreated fellow eyes) were analysed. Both formulations induced significant immediate IOP elevations at T1 (55.6 ± 15.2 mmHg for 8 mg, 54.2 ± 20.4 mmHg for 2 mg) compared to baseline values (p < 0.001). Pressures decreased progressively, approaching baseline by T3 (19.3 ± 5.9 mmHg for 8 mg, 20.5 ± 6.6 mmHg for 2 mg), with no significant differences between doses (p > 0.05). Pre-existing glaucoma emerged as the strongest predictor of sustained IOP elevation, while DMO eyes exhibited higher initial spikes compared to neovascular AMD. Three-month IOP remained stable across both groups. Conclusions Intravitreal administration of aflibercept 8 mg demonstrates IOP dynamics comparable to the 2 mg formulation, with rapid normalization of pressure spikes by 30 min. These findings suggest enhanced monitoring may be beneficial for patients with glaucoma or DMO.
- 1 April 2025
- Published by Springer Nature in Eye
- Vol. 39 (10) , 1933-1939
Early intraocular pressure dynamics following aflibercept 8 mg versus aflibercept 2 mg: a propensity score-matched analysis
Purpose To compare early intraocular pressure (IOP) dynamics following intravitreal injections of aflibercept 8 mg versus aflibercept 2 mg using propensity score-matched analysis with fellow eye controls. Methods This prospective observational study included treatment-naïve patients with neovascular age-related macular degeneration (AMD) or diabetic macular oedema (DMO). Patients received aflibercept 8 mg or 2 mg based on investigator discretion. IOP was measured using iCare rebound tonometry at baseline (T0), 1 min (T1), 10 min (T2), 30 min (T3), and 3 months (T4) after the initial treatment. Untreated fellow eyes served as controls. Secondary analyses evaluated predictors of significant IOP elevation. Results A total of 1820 IOP measurements from 140 eyes (35 treated with aflibercept 8 mg and 35 with aflibercept 2 mg and their respective untreated fellow eyes) were analysed. Both formulations induced significant immediate IOP elevations at T1 (55.6 ± 15.2 mmHg for 8 mg, 54.2 ± 20.4 mmHg for 2 mg) compared to baseline values (p < 0.001). Pressures decreased progressively, approaching baseline by T3 (19.3 ± 5.9 mmHg for 8 mg, 20.5 ± 6.6 mmHg for 2 mg), with no significant differences between doses (p > 0.05). Pre-existing glaucoma emerged as the strongest predictor of sustained IOP elevation, while DMO eyes exhibited higher initial spikes compared to neovascular AMD. Three-month IOP remained stable across both groups. Conclusions Intravitreal administration of aflibercept 8 mg demonstrates IOP dynamics comparable to the 2 mg formulation, with rapid normalization of pressure spikes by 30 min. These findings suggest enhanced monitoring may be beneficial for patients with glaucoma or DMO.
- 29 January 2025
- Published by Springer Nature in Eye
- Vol. 39 (7) , 1349-1355
From pro-re-nata to fixed-interval regimen: evolving real-world treatment paradigms in anti-VEGF therapy for neovascular AMD
Objective To evaluate the impact of evolving treatment paradigms for neovascular age-related macular degeneration (nAMD) by comparing outcomes between two patient cohorts treated with different anti-vascular endothelial growth factor (anti-VEGF) regimens over a decade apart. Methods This retrospective cohort study included 200 treatment-naive nAMD patients divided into two cohorts. Cohort 1 (2009–2010) was treated with a pro re nata (PRN) regimen, involving three initial monthly injections followed by as-needed treatments based on monthly monitoring. Cohort 2 (2019–2021) received a fixed-interval regimen, consisting of three initial monthly injections followed by bimonthly maintenance doses. Primary outcomes included changes in best corrected visual acuity (BCVA) and central retinal thickness (CRT) at 12 months. Secondary outcomes included the number of injections, follow-up visits, and adherence to treatment schedules. Results Cohort 2 demonstrated significantly greater improvement in BCVA (+5.5 vs −2.0 ETDRS letters, p < 0.001) and CRT reduction (−101.7 vs −26.5 μm, p < 0.001) compared to Cohort 1. Patients in Cohort 2 received more injections (7.7 vs 4.8, p < 0.001) but required fewer monitoring visits (3.2 vs 5.1, p < 0.001). Adherence to treatment schedules was markedly higher in Cohort 2 (78% vs 0%, p < 0.001). Conclusions The transition from a PRN to a fixed-interval anti-VEGF regimen significantly improved visual and anatomical outcomes in nAMD patients. Fixed-interval regimens not only enhanced treatment efficacy but also optimized resource utilization, suggesting a superior approach for managing nAMD in a real-world clinical setting.
- 29 January 2025
- Published by Springer Nature in Eye
- Vol. 39 (7) , 1349-1355
From pro-re-nata to fixed-interval regimen: evolving real-world treatment paradigms in anti-VEGF therapy for neovascular AMD
Objective To evaluate the impact of evolving treatment paradigms for neovascular age-related macular degeneration (nAMD) by comparing outcomes between two patient cohorts treated with different anti-vascular endothelial growth factor (anti-VEGF) regimens over a decade apart. Methods This retrospective cohort study included 200 treatment-naive nAMD patients divided into two cohorts. Cohort 1 (2009–2010) was treated with a pro re nata (PRN) regimen, involving three initial monthly injections followed by as-needed treatments based on monthly monitoring. Cohort 2 (2019–2021) received a fixed-interval regimen, consisting of three initial monthly injections followed by bimonthly maintenance doses. Primary outcomes included changes in best corrected visual acuity (BCVA) and central retinal thickness (CRT) at 12 months. Secondary outcomes included the number of injections, follow-up visits, and adherence to treatment schedules. Results Cohort 2 demonstrated significantly greater improvement in BCVA (+5.5 vs −2.0 ETDRS letters, p < 0.001) and CRT reduction (−101.7 vs −26.5 μm, p < 0.001) compared to Cohort 1. Patients in Cohort 2 received more injections (7.7 vs 4.8, p < 0.001) but required fewer monitoring visits (3.2 vs 5.1, p < 0.001). Adherence to treatment schedules was markedly higher in Cohort 2 (78% vs 0%, p < 0.001). Conclusions The transition from a PRN to a fixed-interval anti-VEGF regimen significantly improved visual and anatomical outcomes in nAMD patients. Fixed-interval regimens not only enhanced treatment efficacy but also optimized resource utilization, suggesting a superior approach for managing nAMD in a real-world clinical setting.
- Open Access
- 9 August 2024
- Published by Springer Nature in Ophthalmology and Therapy
- Vol. 13 (10) , 2813-2824
Faricimab in Neovascular AMD Complicated by Pigment Epithelium Detachment: An AI-Assisted Evaluation of Early Morphological Changes
Introduction This study investigates the early temporal changes in pigment epithelial detachment (PED) morphology following treatment with faricimab in patients with neovascular age-related macular degeneration (nAMD). Utilizing an artificial intelligence (AI)-assisted approach, we provide a detailed quantification and characterization of the dynamics of these morphological changes. Methods A prospective observational study was conducted on 22 eyes from 22 treatment-naïve patients with nAMD-associated PED (presenting either type 1 or type 3 macular neovascularization). Participants were administered intravitreal faricimab (6 mg) at baseline and at days 30, 60, and 90. Comprehensive ophthalmic evaluations and spectral-domain optical coherence tomography (SD-OCT) imaging were conducted at baseline and at seven additional follow-up visits on days 1, 7, 14, 30, 60, 90, and 120. An AI-based automated segmentation algorithm was utilized to precisely quantify changes in PED volume, alongside intraretinal (IRF) and subretinal fluid (SRF) volumes, at each time point. Results Treatment with faricimab resulted in a significant reduction in mean PED volume, with an average decrease of 12% at day 1, 29% at day 7, 51% at day 14, 68% at day 30, 72% at day 60, 79% at day 90, and 84% at day 120 (p < 0.0001 for all time points). Similarly rapid and marked reductions were noted in both mean IRF (23.5% at day 1, 90.7% at day 14) and SRF (14.4% at day 1, 91.2% at day 14) volumes. The study also showed a statistically significant improvement in best-corrected visual acuity (BCVA) over the follow-up period, correlating with the reduction in PED volume. Conclusion Faricimab demonstrates early and significant efficacy in improving PED architecture in patients with nAMD. The rapid morphological improvements observed in this study suggest faricimab may represent a valid therapeutic option for PEDs associated with nAMD.
- 9 August 2024
- Published by Springer Nature in Ophthalmology and Therapy
- Vol. 13 (10) , 2813-2824
Open AccessFaricimab in Neovascular AMD Complicated by Pigment Epithelium Detachment: An AI-Assisted Evaluation of Early Morphological Changes
Introduction This study investigates the early temporal changes in pigment epithelial detachment (PED) morphology following treatment with faricimab in patients with neovascular age-related macular degeneration (nAMD). Utilizing an artificial intelligence (AI)-assisted approach, we provide a detailed quantification and characterization of the dynamics of these morphological changes. Methods A prospective observational study was conducted on 22 eyes from 22 treatment-naïve patients with nAMD-associated PED (presenting either type 1 or type 3 macular neovascularization). Participants were administered intravitreal faricimab (6 mg) at baseline and at days 30, 60, and 90. Comprehensive ophthalmic evaluations and spectral-domain optical coherence tomography (SD-OCT) imaging were conducted at baseline and at seven additional follow-up visits on days 1, 7, 14, 30, 60, 90, and 120. An AI-based automated segmentation algorithm was utilized to precisely quantify changes in PED volume, alongside intraretinal (IRF) and subretinal fluid (SRF) volumes, at each time point. Results Treatment with faricimab resulted in a significant reduction in mean PED volume, with an average decrease of 12% at day 1, 29% at day 7, 51% at day 14, 68% at day 30, 72% at day 60, 79% at day 90, and 84% at day 120 (p < 0.0001 for all time points). Similarly rapid and marked reductions were noted in both mean IRF (23.5% at day 1, 90.7% at day 14) and SRF (14.4% at day 1, 91.2% at day 14) volumes. The study also showed a statistically significant improvement in best-corrected visual acuity (BCVA) over the follow-up period, correlating with the reduction in PED volume. Conclusion Faricimab demonstrates early and significant efficacy in improving PED architecture in patients with nAMD. The rapid morphological improvements observed in this study suggest faricimab may represent a valid therapeutic option for PEDs associated with nAMD.
- Open Access
The Present and Future of Optic Pathway Glioma Therapy
Optic pathway gliomas (OPGs) encompass two distinct categories: benign pediatric gliomas, which are characterized by favorable prognosis, and malignant adult gliomas, which are aggressive cancers associated with a poor outcome. Our review aims to explore the established standards of care for both types of tumors, highlight the emerging therapeutic strategies for OPG treatment, and propose potential alternative therapies that, while originally studied in a broader glioma context, may hold promise for OPGs pending further investigation. These potential therapies encompass immunotherapy approaches, molecular-targeted therapy, modulation of the tumor microenvironment, nanotechnologies, magnetic hyperthermia therapy, cyberKnife, cannabinoids, and the ketogenic diet. Restoring visual function is a significant challenge in cases where optic nerve damage has occurred due to the tumor or its therapeutic interventions. Numerous approaches, particularly those involving stem cells, are currently being investigated as potential facilitators of visual recovery in these patients.
Open AccessThe Present and Future of Optic Pathway Glioma Therapy
Optic pathway gliomas (OPGs) encompass two distinct categories: benign pediatric gliomas, which are characterized by favorable prognosis, and malignant adult gliomas, which are aggressive cancers associated with a poor outcome. Our review aims to explore the established standards of care for both types of tumors, highlight the emerging therapeutic strategies for OPG treatment, and propose potential alternative therapies that, while originally studied in a broader glioma context, may hold promise for OPGs pending further investigation. These potential therapies encompass immunotherapy approaches, molecular-targeted therapy, modulation of the tumor microenvironment, nanotechnologies, magnetic hyperthermia therapy, cyberKnife, cannabinoids, and the ketogenic diet. Restoring visual function is a significant challenge in cases where optic nerve damage has occurred due to the tumor or its therapeutic interventions. Numerous approaches, particularly those involving stem cells, are currently being investigated as potential facilitators of visual recovery in these patients.
- Open Access
- 18 May 2023
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 261 (11) , 3299-3306
The ideal intravitreal injection setting: office, ambulatory surgery room or operating theatre? A narrative review and international survey
Purpose: This study reviews evidence and provides recommendations for the ideal setting of intravitreal injection (IVI) administration of vascular endothelial growth factor (VEGF) inhibitors. Methods: A multi-step approach was employed, including content analysis of regulations and guidelines, a systematic literature review, and an international survey assessing perioperative complications and endophthalmitis incidence in relation to injection settings. The literature review searched PubMed and Cochrane databases from 2006 to 2022, focusing on studies reporting correlations between complications and treatment settings. The survey utilized a web-based questionnaire distributed to clinical sites and the international ophthalmic community, with data managed using electronic capture tools. Results: We reviewed regulations and guidelines from 23 countries across five continents, finding significant variation in IVI administration settings. In most countries, IVI is primarily administered in outpatient clean rooms (96%) or offices (39%), while in others, it is restricted to ambulatory surgery rooms or hospital-based operating theatres (4%). The literature review found that endophthalmitis risk after IVI is generally low (0.01% to 0.26% per procedure), with no significant difference between office-based and operating room settings. The international survey (20 centers, 96,624 anti-VEGF injections) found low overall incidences of severe perioperative systemic adverse events and endophthalmitis, independent of injection settings. Conclusion: No significant differences in perioperative complications were observed among various settings, including operating theatres, ambulatory surgery rooms, offices, hospitals, or extra-hospital environments. Choosing the appropriate clinical setting can optimize patient management, potentially increasing effectiveness, quality, productivity, and capacity.
- 18 May 2023
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 261 (11) , 3299-3306
Open AccessThe ideal intravitreal injection setting: office, ambulatory surgery room or operating theatre? A narrative review and international survey
Purpose: This study reviews evidence and provides recommendations for the ideal setting of intravitreal injection (IVI) administration of vascular endothelial growth factor (VEGF) inhibitors. Methods: A multi-step approach was employed, including content analysis of regulations and guidelines, a systematic literature review, and an international survey assessing perioperative complications and endophthalmitis incidence in relation to injection settings. The literature review searched PubMed and Cochrane databases from 2006 to 2022, focusing on studies reporting correlations between complications and treatment settings. The survey utilized a web-based questionnaire distributed to clinical sites and the international ophthalmic community, with data managed using electronic capture tools. Results: We reviewed regulations and guidelines from 23 countries across five continents, finding significant variation in IVI administration settings. In most countries, IVI is primarily administered in outpatient clean rooms (96%) or offices (39%), while in others, it is restricted to ambulatory surgery rooms or hospital-based operating theatres (4%). The literature review found that endophthalmitis risk after IVI is generally low (0.01% to 0.26% per procedure), with no significant difference between office-based and operating room settings. The international survey (20 centers, 96,624 anti-VEGF injections) found low overall incidences of severe perioperative systemic adverse events and endophthalmitis, independent of injection settings. Conclusion: No significant differences in perioperative complications were observed among various settings, including operating theatres, ambulatory surgery rooms, offices, hospitals, or extra-hospital environments. Choosing the appropriate clinical setting can optimize patient management, potentially increasing effectiveness, quality, productivity, and capacity.